Recent Finacing
Recent Raise
InterVenn Biosciences operates an AI-driven mass‑spectrometry glycoproteomics platform (PiP/Vista) that develops blood‑based liquid‑biopsy assays and high‑throughput LDTs for oncology diagnostics and therapy response prediction.
